Use of high-dose botulinum A toxin in benign essential blepharospasm: Is too high too much?

Clinical and Experimental Ophthalmology

Volumn 34, Issue 5, 2006, Pages 441-444

  Pang, Anna L Y ^a   O'Day, Justin ^a  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

Blepharospasm; Botulinum toxin; Idiopathic hemifacial spasm

Indexed keywords

BOTULINUM TOXIN A; PROMETHAZINE;

ADULT; AGED; ARTICLE; BLEPHAROSPASM; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESISTANCE; DRY EYE; EPIPHORA; EYE IRRITATION; FEMALE; FREQUENCY ANALYSIS; HEMIFACIAL SPASM; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PHOTOPHOBIA; PTOSIS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL DISORDER;

AGED; BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; FACIAL MUSCLES; FEMALE; HEMIFACIAL SPASM; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; OCULOMOTOR MUSCLES; RETROSPECTIVE STUDIES;

EID: 33745816669     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2006.01236.x     Document Type: Article

References (18)

1. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044-9.
2. Dressler D. Munchau, antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 2002; 47: 118-21.
3. Attasi MZ, Oshima M. Structure, activity and immune recognition of botulinum neurotoxins. Crit Rev Immunol 1999; 19: 219-60.
4. Greene P, Fahn S. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 213-17.
5. Bakheit AM, Fedorova NV, Skoromets AA, Timberbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004; 75: 1558-61.
6. Gordon MF, Brashear A, Elovic E et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004; 63: 1971-3.
7. Mackie IA. Riolan's muscle: Action and indications for botulinum toxin injections. Eye 2000 14 (Pt 3A): 347-52.
8. Snir M, Weinberger D, Bourla D, Kristal-Shalit O, Dotan G, Axer-Siegel R. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 2003; 136: 99-105.
9. O'Day J. Use of botulinum toxin in neuro-ophthalmology. Curr Opin Ophthalmol 2001; 12: 419-22.
10. McCann J. Benign essential blepharospasm. Int Ophthalmol Clin 2002; 42: 113-21.
11. Curruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci 1987; 14: 42-5.
12. Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988; 95: 1529-34.
13. Jankovic J, Schwartz K. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993; 43: 834-6.
14. Yablon SA, Daggett S. Toxin Neutraliszing Antibody Formation with Botulinum Toxin Type A Treatment. (Poster P01.153), 57th Annual Meeting of the American Academy of Neurology, April 2005.
15. Jankovic J, Schwartz K. Response and immunoresistyence to botulinum toxin injections. Neurology 1995; 45: 1743-6.
16. Dressler D. Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 2000; 247: 809-10.
17. 23rd Annual Benign Essential Blepharospasm Research Foundation (BEBRF). International Conference, University of Alabama, 2004. Tape 7, Side B, 'Why does botulinum toxin fail in some patients?'
18. Siatkowski RM, Tyutyunikov A. Serum antibody production to Botulinum A toxin. Ophthalmology 1993; 100: 1861-6.